Your browser doesn't support javascript.
loading
A tetracationic porphyrin with dual anti-prion activity.
Masone, Antonio; Zucchelli, Chiara; Caruso, Enrico; Lavigna, Giada; Eraña, Hasier; Giachin, Gabriele; Tapella, Laura; Comerio, Liliana; Restelli, Elena; Raimondi, Ilaria; Elezgarai, Saioa R; De Leo, Federica; Quilici, Giacomo; Taiarol, Lorenzo; Oldrati, Marvin; Lorenzo, Nuria L; García-Martínez, Sandra; Cagnotto, Alfredo; Lucchetti, Jacopo; Gobbi, Marco; Vanni, Ilaria; Nonno, Romolo; Di Bari, Michele A; Tully, Mark D; Cecatiello, Valentina; Ciossani, Giuseppe; Pasqualato, Sebastiano; Van Anken, Eelco; Salmona, Mario; Castilla, Joaquín; Requena, Jesús R; Banfi, Stefano; Musco, Giovanna; Chiesa, Roberto.
Afiliação
  • Masone A; Laboratory of Prion Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • Zucchelli C; Biomolecular NMR Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
  • Caruso E; Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.
  • Lavigna G; Laboratory of Prion Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • Eraña H; Centro de Investigación Cooperativa en Biociencias (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.
  • Giachin G; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Carlos III National Health Institute, 28029 Madrid, Spain.
  • Tapella L; Department of Chemical Sciences (DiSC), University of Padua, 35131 Padua, Italy.
  • Comerio L; Laboratory of Prion Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • Restelli E; Laboratory of Prion Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • Raimondi I; Laboratory of Prion Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • Elezgarai SR; Laboratory of Prion Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • De Leo F; Laboratory of Prion Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • Quilici G; Biomolecular NMR Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
  • Taiarol L; Biomolecular NMR Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
  • Oldrati M; Laboratory of Prion Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • Lorenzo NL; Laboratory of Prion Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • García-Martínez S; CIMUS Biomedical Research Institute and Department of Medical Sciences, University of Santiago de Compostela-IDIS, 15782 Santiago de Compostela, Spain.
  • Cagnotto A; Centro de Investigación Cooperativa en Biociencias (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.
  • Lucchetti J; Laboratory of Biochemistry and Protein Chemistry, Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • Gobbi M; Laboratory of Pharmacodynamics and Pharmacokinetics, Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • Vanni I; Laboratory of Pharmacodynamics and Pharmacokinetics, Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • Nonno R; Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, 00161 Rome, Italy.
  • Di Bari MA; Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, 00161 Rome, Italy.
  • Tully MD; Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, 00161 Rome, Italy.
  • Cecatiello V; Structural Biology Group, European Synchrotron Radiation Facility (ESRF), 38000 Grenoble, France.
  • Ciossani G; Department of Experimental Oncology, European Institute of Oncology (IEO) IRCCS, 20141 Milan, Italy.
  • Pasqualato S; Department of Experimental Oncology, European Institute of Oncology (IEO) IRCCS, 20141 Milan, Italy.
  • Van Anken E; Department of Experimental Oncology, European Institute of Oncology (IEO) IRCCS, 20141 Milan, Italy.
  • Salmona M; Protein Transport and Secretion Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
  • Castilla J; Laboratory of Biochemistry and Protein Chemistry, Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • Requena JR; Centro de Investigación Cooperativa en Biociencias (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.
  • Banfi S; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Carlos III National Health Institute, 28029 Madrid, Spain.
  • Musco G; IKERBASQUE, Basque Foundation for Science, 48009 Bilbao, Bizkaia, Spain.
  • Chiesa R; CIMUS Biomedical Research Institute and Department of Medical Sciences, University of Santiago de Compostela-IDIS, 15782 Santiago de Compostela, Spain.
iScience ; 26(9): 107480, 2023 Sep 15.
Article em En | MEDLINE | ID: mdl-37636075
ABSTRACT
Prions are deadly infectious agents made of PrPSc, a misfolded variant of the cellular prion protein (PrPC) which self-propagates by inducing misfolding of native PrPC. PrPSc can adopt different pathogenic conformations (prion strains), which can be resistant to potential drugs, or acquire drug resistance, hampering the development of effective therapies. We identified Zn(II)-BnPyP, a tetracationic porphyrin that binds to distinct domains of native PrPC, eliciting a dual anti-prion effect. Zn(II)-BnPyP binding to a C-terminal pocket destabilizes the native PrPC fold, hindering conversion to PrPSc; Zn(II)-BnPyP binding to the flexible N-terminal tail disrupts N- to C-terminal interactions, triggering PrPC endocytosis and lysosomal degradation, thus reducing the substrate for PrPSc generation. Zn(II)-BnPyP inhibits propagation of different prion strains in vitro, in neuronal cells and organotypic brain cultures. These results identify a PrPC-targeting compound with an unprecedented dual mechanism of action which might be exploited to achieve anti-prion effects without engendering drug resistance.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article